|
1
|
Simon JA and Kingston RE: Mechanisms of
polycomb gene silencing: Knowns and unknowns. Nat Rev Mol Cell
Biol. 10:697–708. 2009.PubMed/NCBI
|
|
2
|
Sparmann A and van Lohuizen M: Polycomb
silencers control cell fate, development and cancer. Nat Rev
Cancer. 6:846–856. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bracken AP and Helin K: Polycomb group
proteins: Navigators of lineage pathways led astray in cancer. Nat
Rev Cancer. 9:773–784. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Russell IF: Auditory perception under
anaesthesia. Anaesthesia. 34:2111979. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sanders LL: Gold therapy for rheumatoid
arthritis. J Ark Med Soc. 73:135–137. 1976.PubMed/NCBI
|
|
7
|
Wang H, Wang L, Erdjument-Bromage H, Vidal
M, Tempst P, Jones RS and Zhang Y: Role of histone H2A
ubiquitination in Polycomb silencing. Nature. 431:873–878. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vidal M: Role of polycomb proteins Ring1A
and Ring1B in the epigenetic regulation of gene expression. Int J
Dev Biol. 53:355–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su WJ, Fang JS, Cheng F, Liu C, Zhou F and
Zhang J: RNF2/Ring1b negatively regulates p53 expression in
selective cancer cell types to promote tumor development. Proc Natl
Acad Sci USA. 110:1720–1725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sánchez-Beato M, Sánchez E,
González-Carreró J, Morente M, Díez A, Sánchez-Verde L, Martín MC,
Cigudosa JC, Vidal M and Piris MA: Variability in the expression of
polycomb proteins in different normal and tumoral tissues. A pilot
study using tissue microarrays. Mod Pathol. 19:684–694. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei M, Jiao D, Han D, Wu J, Wei F, Zheng
G, Guo Z, Xi W, Yang F, Xie P, et al: Knockdown of RNF2 induces
cell cycle arrest and apoptosis in prostate cancer cells through
the upregulation of TXNIP. Oncotarget. 8:5323–5338. 2017.PubMed/NCBI
|
|
12
|
Voncken JW, Roelen BA, Roefs M, de Vries
S, Verhoeven E, Marino S, Deschamps J and van Lohuizen M: Rnf2
(Ring1b) deficiency causes gastrulation arrest and cell cycle
inhibition. Proc Natl Acad Sci USA. 100:2468–2473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yagi A, Machii K, Nishimura H, Shida T and
Nishioka I: Effect of aloe lectin on deoxyribonucleic acid
synthesis in baby hamster kidney cells. Experientia. 41:669–671.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reed SI, Bailly E, Dulic V, Hengst L,
Resnitzky D and Slingerland J: G1 control in mammalian cells. J
Cell Sci Suppl. 18:69–73. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Niculescu AB III, Chen X, Smeets M, Hengst
L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S
and the G2/M cell cycle transitions: pRb is a critical determinant
in blocking DNA replication and in preventing endoreduplication.
Mol Cell Biol. 18:629–643. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dulić V, Kaufmann WK, Wilson SJ, Tlsty TD,
Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition
of cyclin-dependent kinase activities in human fibroblasts during
radiation-induced G1 arrest. Cell. 76:1013–1023. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maertens GN, El Messaoudi-Aubert S, Racek
T, Stock JK, Nicholls J, Rodriguez-Niedenführ M, Gil J and Peters
G: Several distinct polycomb complexes regulate and co-localize on
the INK4a tumor suppressor locus. PLoS One. 4:e63802009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan T, Jiang S, Chung N, Alikhan A, Ni C,
Lee CC and Hornyak TJ: EZH2-dependent suppression of a cellular
senescence phenotype in melanoma cells by inhibition of p21/CDKN1A
expression. Mol Cancer Res. 9:418–429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamamoto Y, Abe A and Emi N: Clarifying
the impact of polycomb complex component disruption in human
cancers. Mol Cancer Res. 12:479–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang W, Qin JJ, Voruganti S, Nag S, Zhou J
and Zhang R: Polycomb group (PcG) proteins and human cancers:
Multifaceted functions and therapeutic implications. Med Res Rev.
35:1220–1267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette sTR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ,
Li SX, Wang XL and Peng ZH: Expression level of Bmi-1 oncoprotein
is associated with progression and prognosis in colon cancer. J
Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garcia JF, Camacho FI, Morente M, Fraga M,
Montalbán C, Alvaro T, Bellas C, Castaño A, Díez A, Flores T, et
al: Hodgkin and reed-sternberg cells harbor alterations in the
major tumor suppressor pathways and cell-cycle checkpoints:
Analyses using tissue microarrays. Blood. 101:681–689. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bosch A, Panoutsopoulou K, Corominas JM,
Gimeno R, Moreno-Bueno G, Martín-Caballero J, Morales S, Lobato T,
Martínez-Romero C, Farias EF, et al: The polycomb group protein
RING1B is overexpressed in ductal breast carcinoma and is required
to sustain FAK steady state levels in breast cancer epithelial
cells. Oncotarget. 5:2065–2076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen W, Peng C, Kim MO, Jeong Ho C, Zhu F,
Yao K, Zykova T, Ma W, Carper A, Langfald A, et al: Knockdown of
RNF2 induces apoptosis by regulating MDM2 and p53 stability.
Oncogene. 33:421–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ortega S, Malumbres M and Barbacid M:
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim
Biophys Acta. 1602:73–87. 2002.PubMed/NCBI
|
|
33
|
Pérez-Sayáns M, Suárez-Peñaranda JM,
Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM and Garcia-Garcia
A: p16 (INK4a)/CDKN2 expression and its relationship with oral
squamous cell carcinoma is our current knowledge enough? Cancer
Lett. 306:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Llanos S, Clark PA, Rowe J and Peters G:
Stabilization of p53 by p14ARF without relocation of MDM2 to the
nucleolus. Nat Cell Biol. 3:445–452. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dominguez G, Silva J, Garcia JM, Silva JM,
Rodriguez R, Muñoz C, Chacón I, Sanchez R, Carballido J, Colás A,
et al: Prevalence of aberrant methylation of p14ARF over p16INK4a
in some human primary tumors. Mutat Res. 530:9–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng M, Olivier P, Diehl JA, Fero M,
Roussel MF, Roberts JM and Sherr CJ: The p21(Cip1) and p27(Kip1)
CDK ‘inhibitors’ are essential activators of cyclin D-dependent
kinases in murine fibroblasts. EMBO J. 18:1571–1583. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carnero A, Hudson JD, Price CM and Beach
DH: p16INK4A and p19ARF act in overlapping pathways in cellular
immortalization. Nat Cell Biol. 2:148–155. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kerkhoff E and Rapp UR: Cell cycle targets
of Ras/Raf signalling. Oncogene. 17:(11 Reviews). 1457–1462. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Villabona C, Novials A, Soler J, Morató J,
Gómez JM and Navarro MA: Hormonal evaluation of 27 patients with
acromegaly. Med Clin (Barc). 84:219–222. 1985.(In Spanish).
PubMed/NCBI
|
|
40
|
Sen N, Satija YK and Das S: PGC-1α, a key
modulator of p53, promotes cell survival upon metabolic stress. Mol
Cell. 44:621–634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fiskus W, Wang Y, Sreekumar A, Buckley KM,
Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al:
Combined epigenetic therapy with the histone methyltransferase EZH2
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor
panobinostat against human AML cells. Blood. 114:2733–2743. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang
W, Wang D, Ye J, Jiang H, Yang J and Cheng J: The polycomb group
protein EZH2 is a novel therapeutic target in tongue cancer.
Oncotarget. 4:2532–2549. 2013. View Article : Google Scholar : PubMed/NCBI
|
